Chronic News and Research

RSS

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components.

18 May 2010

ICF International awarded multi-year contract to support community action in reducing chronic disease

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a new $11.6 million multi-year contract by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, to develop a resource center for broad-scale community action to reduce chronic disease.

18 May 2010

High school student studies effects of repeated x-rays in HMV children admitted for pneumonia

You expect to find leading experts in the fields of pulmonary, critical care and sleep medicine presenting their research at the annual ATS International Conference-physicians and professors, basic scientists, fellows and post-docs, certainly. High school students? Not so much.

18 May 2010

Study confirms genetic overlap for susceptibility to COPD and lung cancer

New research shows genes that make smokers more likely to develop chronic obstructive pulmonary disease (COPD), or emphysema, are also closely linked to an increased likelihood of developing lung cancer, according to studies presented today at the American Thoracic Society's annual meeting.

18 May 2010

Sleep apnea increases insulin resistance: Study

Sleep apnea may cause metabolic changes that increase insulin resistance, according to researchers from the University of Pittsburgh Medical Center. The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

18 May 2010

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.

18 May 2010

Family plays vital role in children's oral health: General Dentistry

Parents are a child's first teacher in life and play a significant role in maintaining his or her overall health. Providing oral health education to mothers and families is essential to teaching children healthy habits and preventing early childhood tooth decay, according to an article published in the May/June 2010 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General Dentistry.

18 May 2010

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.

18 May 2010

REVEAL risk score calculator provides innovative approach to better understand PAH

Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.

18 May 2010

Pfizer, Washington University announce indications discovery collaboration

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

18 May 2010

Caffeine normalizes brain function and prevents cognitive decline

Although caffeine is the most widely consumed psychoactive drug worldwide, its potential beneficial effect for maintenance of proper brain functioning has only recently begun to be adequately appreciated. Substantial evidence from epidemiological studies and fundamental research in animal models suggests that caffeine may be protective against the cognitive decline seen in dementia and Alzheimer's disease (AD).

18 May 2010

Electrical muscle stimulation prevents critical illness polynueromyopathy

Electrical muscle stimulation (EMS) can prevent critical illness polyneuromyopathy (CIPNM), according to Greek researchers. CIPNM is an acquired limb and respiratory muscle weakness that is a common and serious problem among intensive care unit patients, and can result in prolonged ICU and hospital stay. EMS can also shorten the duration of weaning from mechanical ventilation and the length of ICU stay.

18 May 2010

NMES may reduce muscle atrophy in patients with severe COPD: Researchers

Neuromuscular electrical stimulation may reduce muscle atrophy in patients with severe chronic obstructive pulmonary disease, according to Canadian researchers.

18 May 2010

Tests of kidney function, damage predict risk of death from cardiovascular diseases: Study

Common tests of kidney function and damage predict the risk of death from cardiovascular diseases and all causes, according to a paper from the Chronic Kidney Disease Prognosis Consortium, established last year by Kidney Disease: Improving Global Outcomes.

18 May 2010

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

FDA issues complete response letter for roflumilast NDA

Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

18 May 2010

Cardiocom releases new pulse oximeter

Cardiocom today announced the release of its new pulse oximeter. Cardiocom's internally developed pulse oximeter offers better integration with its telehealth platform. Cardiocom designs and manufactures telehealth communication devices and vital sign peripherals including: blood pressure system, weight scale, and now offers its new pulse oximeter.

17 May 2010

TriReme Medical receives FDA expanded clearance for GliderXtreme PTA balloon catheter

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its GliderXtreme™ PTA balloon catheter. GliderXtreme™ is now approved for the percutaneous transluminal treatment of lesions in the peripheral vasculature in balloon diameters from 2.0 – 5.0mm and in balloon lengths up to 200mm.

17 May 2010

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

Chronic News and Research

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

ICF International awarded multi-year contract to support community action in reducing chronic disease

High school student studies effects of repeated x-rays in HMV children admitted for pneumonia

Study confirms genetic overlap for susceptibility to COPD and lung cancer

Sleep apnea increases insulin resistance: Study

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

Family plays vital role in children's oral health: General Dentistry

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

REVEAL risk score calculator provides innovative approach to better understand PAH

Pfizer, Washington University announce indications discovery collaboration

Caffeine normalizes brain function and prevents cognitive decline

Electrical muscle stimulation prevents critical illness polynueromyopathy

NMES may reduce muscle atrophy in patients with severe COPD: Researchers

Tests of kidney function, damage predict risk of death from cardiovascular diseases: Study

Inovio Pharmaceuticals first-quarter net loss attributable to common stockholders decreases to $2.3M

152 research and training grants awarded to researchers at 93 institutions nationwide

FDA issues complete response letter for roflumilast NDA

Cardiocom releases new pulse oximeter

TriReme Medical receives FDA expanded clearance for GliderXtreme PTA balloon catheter

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News